Eli Lilly and Company $LLY Stock Holdings Boosted by Farther Finance Advisors LLC

Farther Finance Advisors LLC boosted its stake in Eli Lilly and Company (NYSE:LLY) by 55.4% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 68,083 shares of the company’s stock after acquiring an additional 24,274 shares during the period. Eli Lilly and Company accounts for about 0.5% of Farther Finance Advisors LLC’s holdings, making the stock its 29th biggest position. Farther Finance Advisors LLC’s holdings in Eli Lilly and Company were worth $78,778,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. grew its stake in shares of Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after purchasing an additional 1,046,558 shares during the last quarter. State Street Corp raised its stake in shares of Eli Lilly and Company by 1.7% during the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock worth $43,438,262,000 after purchasing an additional 605,752 shares during the last quarter. Bank of America Corp DE acquired a new stake in shares of Eli Lilly and Company during the second quarter worth $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Eli Lilly and Company by 1.9% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock worth $8,647,153,000 after purchasing an additional 137,364 shares during the period. Finally, Jennison Associates LLC grew its position in Eli Lilly and Company by 7.9% in the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock valued at $6,550,587,000 after buying an additional 400,538 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

LLY has been the topic of several recent research reports. BMO Capital Markets reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, October 1st. The Goldman Sachs Group lifted their target price on shares of Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the company a “buy” rating in a report on Thursday, September 17th. Bank of America boosted their price target on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. HSBC increased their price target on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a report on Thursday, September 10th. Finally, UBS Group set a $1,376.00 price objective on Eli Lilly and Company in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,313.43.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded down $18.95 during trading on Thursday, hitting $1,169.77. 3,090,036 shares of the company were exchanged, compared to its average volume of 2,974,879. The company has a market cap of $1.10 trillion, a price-to-earnings ratio of 39.25, a PEG ratio of 1.42 and a beta of 0.46. Eli Lilly and Company has a 1 year low of $783.85 and a 1 year high of $1,292.65. The firm’s fifty day moving average price is $1,173.51 and its 200 day moving average price is $1,094.59. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter last year, the firm posted $6.31 EPS. The business’s revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, sell-side analysts expect that Eli Lilly and Company will post 36.66 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the sale, the chief accounting officer owned 1,526 shares of the company’s stock, valued at $1,808,325.26. The trade was a 56.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is owned by company insiders.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Higher analyst price target: Cantor Fitzgerald raised its target for Eli Lilly from $1,410 to $1,440 and maintained an “overweight” rating, implying substantial upside from recent levels. Benzinga report
• Positive Sentiment: Pipeline diversification remains a key bullish argument. Investors are highlighting next-generation obesity candidate retatrutide, which has shown greater weight loss in trials than Zepbound and could be filed with regulators in 2027. Lilly is also expanding its early-stage Alzheimer’s research and testing obesity drug eloralintide alongside birth control. Eli Lilly obesity business article
• Positive Sentiment: Growth extends beyond GLP-1 drugs. Jaypirca, Inluriyo and Retevmo could support oncology growth, while a new research and licensing agreement with InnoCare covers as many as five drug targets. Commentators argue that Lilly’s manufacturing expansion and broad pipeline create a growth flywheel beyond Mounjaro and Zepbound. Lilly oncology portfolio article
• Neutral Sentiment: Technical support is being watched. A move around the 50-day moving average may signal short-term stabilization, but technical indicators do not resolve the stock’s valuation or fundamental risks. LLY moving average analysis
• Negative Sentiment: Valuation and competition are weighing on sentiment. Lilly trades at a premium multiple, leaving the shares sensitive to pricing pressure, increased competition in obesity medicines and any slowdown in GLP-1 demand. New WHO childhood-obesity guidance may also create uncertainty around how these therapies are used in younger patients. WHO obesity guidance article

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.